company background image
RXRX logo

Recursion Pharmaceuticals NasdaqGS:RXRX Stock Report

Last Price

US$8.01

Market Cap

US$2.3b

7D

13.3%

1Y

5.4%

Updated

08 Dec, 2024

Data

Company Financials +

Recursion Pharmaceuticals, Inc.

NasdaqGS:RXRX Stock Report

Market Cap: US$2.3b

RXRX Stock Overview

Operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. More details

RXRX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth1/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Recursion Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Recursion Pharmaceuticals
Historical stock prices
Current Share PriceUS$8.01
52 Week HighUS$15.74
52 Week LowUS$5.60
Beta0.84
11 Month Change12.82%
3 Month Change30.88%
1 Year Change5.39%
33 Year Change-57.80%
5 Year Changen/a
Change since IPO-74.41%

Recent News & Updates

Recursion: No News Isn't Good News When It Comes To Vanilla Pipeline

Nov 20

Analysts Are Betting On Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) With A Big Upgrade This Week

Nov 10
Analysts Are Betting On Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) With A Big Upgrade This Week

Recent updates

Recursion: No News Isn't Good News When It Comes To Vanilla Pipeline

Nov 20

Analysts Are Betting On Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) With A Big Upgrade This Week

Nov 10
Analysts Are Betting On Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) With A Big Upgrade This Week

Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) Share Price Could Signal Some Risk

Nov 08
Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) Share Price Could Signal Some Risk

Recursion: AI Is Only As Good As The Data

Sep 11

Recursion: Path Forward For REC-994 Remains Despite Mixed Response

Sep 04

Earnings Beat: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Aug 12
Earnings Beat: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Recursion Pharmaceuticals: AI-Driven 'TechBio' With Upcoming Catalysts

Aug 01

Recursion Pharmaceuticals: More Of A TechBio Industrializing Drug Discovery

Jun 24

Recursion Pharmaceuticals: Catalysts Are Coming And Success Is A Must

Jun 14

Revenues Not Telling The Story For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) After Shares Rise 25%

May 22
Revenues Not Telling The Story For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) After Shares Rise 25%

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

May 12
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

Revisiting Recursion: Big Bets, Big Data, And The Big Cash Burn Rate

Apr 10

Recursion: Exercising Caution Prior To Q3 Data Release (Rating Downgrade)

Mar 20

Recursion Pharmaceuticals (NASDAQ:RXRX) Is Using Debt Safely

Jan 31
Recursion Pharmaceuticals (NASDAQ:RXRX) Is Using Debt Safely

Recursion Pharmaceuticals: More Hype Than Substance Amid Signs Of Progress

Jan 12

Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) 45% Price Boost Is Out Of Tune With Revenues

Dec 09
Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) 45% Price Boost Is Out Of Tune With Revenues

What You Need To Know About The Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Analyst Downgrade Today

May 09
What You Need To Know About The Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Analyst Downgrade Today

Shareholder Returns

RXRXUS BiotechsUS Market
7D13.3%-0.8%1.0%
1Y5.4%13.6%32.4%

Return vs Industry: RXRX underperformed the US Biotechs industry which returned 13.6% over the past year.

Return vs Market: RXRX underperformed the US Market which returned 32.4% over the past year.

Price Volatility

Is RXRX's price volatile compared to industry and market?
RXRX volatility
RXRX Average Weekly Movement11.3%
Biotechs Industry Average Movement10.2%
Market Average Movement6.3%
10% most volatile stocks in US Market16.5%
10% least volatile stocks in US Market3.1%

Stable Share Price: RXRX's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: RXRX's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2013500Chris Gibsonwww.recursion.com

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer.

Recursion Pharmaceuticals, Inc. Fundamentals Summary

How do Recursion Pharmaceuticals's earnings and revenue compare to its market cap?
RXRX fundamental statistics
Market capUS$2.30b
Earnings (TTM)-US$377.75m
Revenue (TTM)US$65.18m

35.2x

P/S Ratio

-6.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RXRX income statement (TTM)
RevenueUS$65.18m
Cost of RevenueUS$327.89m
Gross Profit-US$262.71m
Other ExpensesUS$115.04m
Earnings-US$377.75m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.32
Gross Margin-403.03%
Net Profit Margin-579.51%
Debt/Equity Ratio0.2%

How did RXRX perform over the long term?

See historical performance and comparison